SG2014008080A - Methods of treatment of retinal degeneration diseases - Google Patents

Methods of treatment of retinal degeneration diseases

Info

Publication number
SG2014008080A
SG2014008080A SG2014008080A SG2014008080A SG2014008080A SG 2014008080 A SG2014008080 A SG 2014008080A SG 2014008080 A SG2014008080 A SG 2014008080A SG 2014008080 A SG2014008080 A SG 2014008080A SG 2014008080 A SG2014008080 A SG 2014008080A
Authority
SG
Singapore
Prior art keywords
treatment
methods
retinal degeneration
degeneration diseases
diseases
Prior art date
Application number
SG2014008080A
Other languages
English (en)
Inventor
Maria Pia Cosma
Daniela Sanges
Original Assignee
Maria Pia Cosma
Daniela Sanges
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maria Pia Cosma, Daniela Sanges filed Critical Maria Pia Cosma
Publication of SG2014008080A publication Critical patent/SG2014008080A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG2014008080A 2011-08-05 2012-08-06 Methods of treatment of retinal degeneration diseases SG2014008080A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11176713A EP2554662A1 (en) 2011-08-05 2011-08-05 Methods of treatment of retinal degeneration diseases
PCT/EP2012/065327 WO2013020945A1 (en) 2011-08-05 2012-08-06 Methods of treatment of retinal degeneration diseases

Publications (1)

Publication Number Publication Date
SG2014008080A true SG2014008080A (en) 2014-03-28

Family

ID=46826437

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2014008080A SG2014008080A (en) 2011-08-05 2012-08-06 Methods of treatment of retinal degeneration diseases

Country Status (15)

Country Link
US (1) US20140199277A1 (enExample)
EP (2) EP2554662A1 (enExample)
JP (1) JP2014527407A (enExample)
KR (1) KR20140068936A (enExample)
CN (1) CN104011203A (enExample)
AR (1) AR087471A1 (enExample)
AU (1) AU2012293681A1 (enExample)
BR (1) BR112014002718A8 (enExample)
CA (1) CA2844106A1 (enExample)
CO (1) CO7081142A2 (enExample)
IL (1) IL230830A0 (enExample)
MX (1) MX2014001475A (enExample)
RU (1) RU2014108478A (enExample)
SG (1) SG2014008080A (enExample)
WO (1) WO2013020945A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012314330B2 (en) * 2011-09-29 2017-08-24 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compositions and methods for the treatment of degenerative retinal conditions
SG11201605833PA (en) 2014-01-17 2016-08-30 Sumitomo Chemical Co Method for manufacturing ciliary margin stem cells
KR102612871B1 (ko) * 2014-09-16 2023-12-13 젠자임 코포레이션 마이오실린(myoc) 녹내장을 치료하기 위한 아데노-관련 바이러스 벡터
RU2578526C1 (ru) * 2014-12-25 2016-03-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ получения органной культуры хороидально-пигментного комплекса из глаза взрослого донора-трупа
RU2569481C1 (ru) * 2014-12-25 2015-11-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ получения культуры клеток ретинального пигментного эпителия из глаза взрослого донора-трупа
KR101779932B1 (ko) * 2015-09-15 2017-09-21 주식회사 스템랩 나노그(Nanog)를 도입한 양수 내 태아 유래 중간엽 줄기세포를 이용한 육모 촉진용 조성물의 제조방법
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
KR101674622B1 (ko) * 2016-07-07 2016-11-09 국민대학교산학협력단 세스퀴테르펜 유도체의 신규한 용도
CA3032153A1 (en) * 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
WO2018106369A2 (en) * 2016-11-06 2018-06-14 Nanoscope Technologies Llc Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof
EP3616120B1 (en) 2017-04-27 2024-09-04 Retinascan Limited System and method for automated funduscopic image analysis
EP3625224B1 (en) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
WO2018210992A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
WO2018210994A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Phenyl derivatives as pge2 receptor modulators
AU2018268311B2 (en) 2017-05-18 2022-02-10 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
US20210139844A1 (en) * 2017-06-15 2021-05-13 University Of North Texas Health Science Center Reprogramming fibroblasts to retinal cells
EP3668487A4 (en) * 2017-08-20 2020-08-26 The Regents of the University of California MODULATION OF WNT5A TO TREAT GLAUCOMA
EP3773638A4 (en) * 2018-04-06 2022-04-06 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS FOR TREATING LOSS OF VISION BY GENERATION OF ROD PHOTORECEPTORS FROM MÜLLER GLIAL CELLS
EP3937955A4 (en) * 2019-03-15 2022-12-07 The Schepens Eye Research Institute, Inc. ISOLATION, ENHANCEMENT AND EXPANSION OF CONICAL PROGENITOR CELLS AND THEIR USES
CN110706164A (zh) * 2019-09-03 2020-01-17 北京爱博同心医学科技有限公司 基于增强现实的管状视野图像变形显示方法及眼镜
US20230034053A1 (en) * 2019-09-25 2023-02-02 The Board Of Trustees Of The Leland Stanford Junior University Metabolic rescue of retinal degeneration
KR20210119766A (ko) * 2020-03-25 2021-10-06 서울대학교병원 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물
KR102655748B1 (ko) * 2023-06-08 2024-04-05 충북대학교 산학협력단 고포도당 조건에서의 중간엽 줄기세포의 생존율을 증가시키는 방법
KR102655735B1 (ko) * 2023-06-09 2024-04-05 충북대학교 산학협력단 당뇨성 망막병증의 예방 및 치료를 위한 타크로리무스 전처리 줄기세포
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6128654A (en) 1997-02-14 2000-10-03 Advanced Micro Devices, Inc. Method and apparatus for transmitting multiple copies by replicating data identifiers
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
AU784748B2 (en) 1999-12-17 2006-06-08 Novartis Vaccines And Diagnostics, Inc. Bicyclic inhibitors of glycogen synthase kinase 3
ATE384704T1 (de) 1999-12-17 2008-02-15 Novartis Vaccines & Diagnostic Pyrazin-basierte hemmer der glycogen-synthase- kinase 3
CN100506801C (zh) 2000-09-06 2009-07-01 诺华疫苗和诊断公司 糖元合成酶激酶3的抑制剂
ES2302106T3 (es) 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
JP4523271B2 (ja) 2001-06-01 2010-08-11 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール化合物
JP4656838B2 (ja) 2002-02-06 2011-03-23 バーテックス ファーマシューティカルズ インコーポレイテッド Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物
JP2005525362A (ja) 2002-03-01 2005-08-25 カイロン コーポレイション 虚血の処置のための方法および組成物
US20050129665A1 (en) 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US7838290B2 (en) * 2002-07-25 2010-11-23 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
DE60333762D1 (de) 2002-08-23 2010-09-23 Novartis Vaccines & Diagnostic Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren
JP2006506383A (ja) 2002-10-21 2006-02-23 カイロン コーポレイション グリコーゲンシンターゼキナーゼ３のインヒビター
EP1624758A4 (en) * 2003-05-02 2007-03-07 Scripps Research Inst HEMOPOETIC STEM CELLS AND METHOD FOR THE TREATMENT OF EYE-RELATED VASCULAR DISEASES USING THESE STEM CELLS
KR20060056377A (ko) 2003-08-13 2006-05-24 카이론 코포레이션 Ｇｓｋ-3 억제제 및 그것의 사용
JP2008512376A (ja) * 2004-09-03 2008-04-24 ザ・スクリプス・リサーチ・インステイチユート 単離された系統陰性造血幹細胞及びこれを用いた治療方法
US7850960B2 (en) * 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
JP5173442B2 (ja) 2005-02-24 2013-04-03 ザ スクリプス リサーチ インスティチュート 未熟児網膜症及び関連網膜症疾患の治療のための方法
US20070231306A1 (en) * 2005-02-24 2007-10-04 The Scripps Research Institute Isolated myeloid-like cell populations and methods of treatment therewith
CA2613889A1 (en) * 2005-06-08 2006-12-14 Centocor, Inc. A cellular therapy for ocular degeneration
EA201070022A1 (ru) * 2007-06-15 2010-06-30 Гарнет Байотерапьютикс Инк. Лечение заболеваний и нарушений с использованием самообновляющихся образующих колонии клеток, культивированных и размноженных in vitro
EP2090649A1 (en) 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
GB0816577D0 (en) * 2008-09-11 2008-10-15 Axordia Ltd Growth factor
EP2486126B1 (en) * 2009-10-06 2017-12-06 SNU R & DB Foundation Method for differentiation into retinal cells from stem cells

Also Published As

Publication number Publication date
CN104011203A (zh) 2014-08-27
AR087471A1 (es) 2014-03-26
EP2739723A1 (en) 2014-06-11
US20140199277A1 (en) 2014-07-17
RU2014108478A (ru) 2015-09-10
JP2014527407A (ja) 2014-10-16
WO2013020945A1 (en) 2013-02-14
AU2012293681A1 (en) 2014-03-06
NZ621345A (en) 2015-09-25
CA2844106A1 (en) 2013-02-14
IL230830A0 (en) 2014-03-31
MX2014001475A (es) 2014-07-22
CO7081142A2 (es) 2014-10-10
BR112014002718A2 (pt) 2017-06-13
WO2013020945A9 (en) 2013-04-04
EP2554662A1 (en) 2013-02-06
BR112014002718A8 (pt) 2017-06-20
KR20140068936A (ko) 2014-06-09

Similar Documents

Publication Publication Date Title
SG2014008080A (en) Methods of treatment of retinal degeneration diseases
IL274469A (en) Compositions, uses and methods for the treatment of metabolic disorders and diseases
IL229257A0 (en) Preparations and methods for the treatment of diseases related to the retina of the eye
ZA201309557B (en) Methods of treatment for retinal diseases
EP2717855A4 (en) PROCESSING METHODS
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
EP2773754A4 (en) Methods of Treatment
ZA201402056B (en) (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders
IL229017B (en) Oxidative diseases of the retina
EP2906295A4 (en) METHODS OF TREATING OCULAR DISEASES
IL237772B (en) Methods and preparations for the treatment of retinal degeneration
SG10201703677VA (en) Methods of treating s. aureus-associated diseases
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
IL229705A0 (en) Methods for the treatment or prevention of neurological diseases
IL235874A0 (en) Treatment of ocular inflammatory diseases by laquinimod
IL239273A0 (en) A method of treating diseases
IL228405A0 (en) Methods for targeted treatment of degeneration of the frontotemporal lobe
HK1196022A (zh) 视网膜变性疾病的治疗方法
EP2911662A4 (en) METHOD OF TREATING A DISEASE
EP2791324A4 (en) PROCESSING METHOD
PT2704747T (pt) Colírios para tratamento de conjuntivocálase
HK1193343A (en) Methods for treating diseases of the retina
IL231052A0 (en) (Bacterio) chlorophyll photosensitizers for the treatment of eye diseases and disorders
AU2011903764A0 (en) Treatment of bone diseases
GB201109737D0 (en) Methods of treatment